EGFR and non-small cell lung carcinoma: Similar results were seen in exploratory subgroup analyses in patients diagnosed with advanced EGFR Mut+ NSCLC after May 2013 (n = 744), following the US Food and Drug Administration approval of afatinib in this setting.